Biotech

All Articles

Ionis centers eye condition coming from targets of Roche-partnered possibility after data disappoint

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has fallen short of desires, motivati...

Biogen's CEO pointed out no high-risk deals in 2023. He's ready to be bold

.While Biogen's pharma peers are actually searching for late-stage properties along with little bit ...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Bio has been a biotech looking for a pipeline after it scrapped its own lead assets over the...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually restored civil rights to an early Alzheimer's illness program to Denali Therapi...

Takeda taps brand-new mind of US oncology company-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings and als...

Vertex, hammered by AATD once again, goes down 2 resources on dispose of heap

.Vertex's attempt to address an uncommon hereditary illness has attacked another problem. The biotec...

Vir gains 3 T-cell engagers from Sanofi, lays off 25% of workers

.Vir Medical's second-quarter earnings report had not been short of significant news. The company in...

Galapagos pauses CAR-T tissue treatment litigation over Parkinsonism scenario

.Galapagos has actually stopped briefly application in a test of a BCMA-directed CAR-T cell therapy,...

James Wilson leaving behind Penn to launch 2 new biotechs

.After more than 30 years, gene treatment trendsetter James Wilson M.D., Ph.D., is leaving the Unive...

3 biotechs make an effort to defeat the summer months warmth through dropping workers

.As biotechs try to transform a fresh webpage in August, at the very least three firms have actually...